PROTEOMICS AND METABOLOMICS SHARED RESOURCE Project Summary The Bioanalytical Laboratory Shared Resource scored as ?excellent? during the previous review. To reflect the evolving needs of Wake Forest Baptist Comprehensive Cancer Center (WFBCCC) members, it has since been restructured to form the Proteomics and Metabolomics Shared Resource (PMSR). This Shared Resource provides advanced mass spectrometry services, technologies, and scientific consultation for global and targeted proteomics, metabolomics and lipidomics studies. The PMSR specializes in discovery, identification, characterization, and quantification of biomolecules, including proteins, lipids and other metabolites by mass spectrometry and biochemical methods in a variety of biological specimens; chromatography of proteins, peptides, lipids, nucleic acids and chemical compounds; measurement of bioenergy metabolism; and targeted multiplex analysis using immunoassays. Assets of PMSR include 1) Three major mass spectrometry systems for metabolomics and lipidomics analysis, including a new Shimadzu LCMS-8050 LC/MS/MS System; 2) A newly-installed Thermo Q-Exactive HF mass spectrometer with data-independent acquisition and parallel reaction monitoring capabilities interfaced with a nanoLC system for proteomics analysis; 3) Access to a broad range of instruments and expertise at RTI Metabolomics, now part of a broad partnership with the WFBCCC and PMSR; and 4) Expertise of personnel. The PMSR is directed by Cristina M. Furdui, Ph.D., and Mark O. Lively, Ph.D., and currently employs four individuals (Jingyun Lee, Ph.D, Hanzhi Wu, Ph.D., Brian Fulp, B.S., and Mark Morris, B.S.) for a combined total of 2.7 FTE (1.15 CCSG FTEs requested). During the last full reporting year (11/1/2014 ? 10/31/2015), the PMSR supported the research of 24 faculty members of Wake Forest Baptist Medical Center and 6 external researchers, analyzing 2,116 samples (approximately 90% of PMSR capacity). Usage by WFBCCC members with peer-reviewed funding during this period was 47% (75% based on number of samples). The Institution's support of the PMSR is reflected in its investment of close to $1M for purchasing of new instrumentation and hiring of additional personnel, a significant cost-sharing that increases the value of the CCSG investment in PMSR. The Shared Resource is reviewed annually by the Institution's Centers and Cores Advisory Committee, which is within Biomedical Research Services and Administration, and reports to the Dean. In addition, quarterly meetings of the Shared Resource Directors are held and include reports/discussions on activity, best practices, enhanced capabilities, and administrative management techniques. These are chaired by Kounosuke Watabe, Ph.D., the Associate Director for Shared Resources. The WFBCCC Senior Leadership has the final responsibility for evaluating the effectiveness of PMSR in supporting the Cancer Center mission.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA012197-44
Application #
9636543
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2019-02-01
Budget End
2020-01-31
Support Year
44
Fiscal Year
2019
Total Cost
Indirect Cost
Name
Wake Forest University Health Sciences
Department
Type
DUNS #
937727907
City
Winston-Salem
State
NC
Country
United States
Zip Code
27157
Westcott, Marlena M; Clemens, Elene A; Holbrook, Beth C et al. (2018) The choice of linker for conjugating R848 to inactivated influenza virus determines the stimulatory capacity for innate immune cells. Vaccine 36:1174-1182
Ruiz, Jimmy; Miller, Antonius A; Tooze, Janet A et al. (2018) Frailty assessment predicts toxicity during first cycle chemotherapy for advanced lung cancer regardless of chronologic age. J Geriatr Oncol :
Levine, Edward A; Votanopoulos, Konstantinos I; Shen, Perry et al. (2018) A Multicenter Randomized Trial to Evaluate Hematologic Toxicities after Hyperthermic Intraperitoneal Chemotherapy with Oxaliplatin or Mitomycin in Patients with Appendiceal Tumors. J Am Coll Surg 226:434-443
Addington, Elizabeth L; Sohl, Stephanie J; Tooze, Janet A et al. (2018) Convenient and Live Movement (CALM) for women undergoing breast cancer treatment: Challenges and recommendations for internet-based yoga research. Complement Ther Med 37:77-79
Park, Sun H; Keller, Evan T; Shiozawa, Yusuke (2018) Bone Marrow Microenvironment as a Regulator and Therapeutic Target for Prostate Cancer Bone Metastasis. Calcif Tissue Int 102:152-162
Haas, Karen M; Johnson, Kristen L; Phipps, James P et al. (2018) CD22 Promotes B-1b Cell Responses to T Cell-Independent Type 2 Antigens. J Immunol 200:1671-1681
Suo, Xubin; Eldridge, Brittany N; Zhang, Han et al. (2018) P-Glycoprotein-Targeted Photothermal Therapy of Drug-Resistant Cancer Cells Using Antibody-Conjugated Carbon Nanotubes. ACS Appl Mater Interfaces 10:33464-33473
Widner, D Brooke; Park, Sun H; Eber, Matthew R et al. (2018) Interactions Between Disseminated Tumor Cells and Bone Marrow Stromal Cells Regulate Tumor Dormancy. Curr Osteoporos Rep 16:596-602
Liu, Liang; Ruiz, Jimmy; O'Neill, Stacey S et al. (2018) Favorable outcome of patients with lung adenocarcinoma harboring POLE mutations and expressing high PD-L1. Mol Cancer 17:81
Sirkisoon, Sherona R; Carpenter, Richard L; Rimkus, Tadas et al. (2018) Interaction between STAT3 and GLI1/tGLI1 oncogenic transcription factors promotes the aggressiveness of triple-negative breast cancers and HER2-enriched breast cancer. Oncogene 37:2502-2514

Showing the most recent 10 out of 548 publications